Literature DB >> 8409049

Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy.

M Bikkina1, M G Larson, D Levy.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the long-term prognostic role of asymptomatic ventricular arrhythmias in original Framingham Heart Study subjects and Framing-ham Offspring Study subjects who had echocardiographic evidence of left ventricular hypertrophy.
BACKGROUND: Echocardiographically determined left ventricular hypertrophy is associated with increased risk for ventricular arrhythmias. There are no population-based data available with regard to the long-term prognostic implications of asymptomatic ventricular arrhythmias in subjects with left ventricular hypertrophy.
METHODS: In a population-based cohort study, we studied 224 men and 393 women with echocardiographically determined left ventricular hypertrophy who were free of coronary heart disease and had 1-h ambulatory electrocardiograms at the baseline examination. The age-adjusted prevalence of complex or frequent ventricular arrhythmias (> 30 ventricular premature beats/h, multiform premature complexes, couplets, ventricular tachycardia or R on T ventricular premature complexes) was 28% (51 of 224) in men and 17% (71 of 393) in women. The mean follow-up period was 5.7 years for cohort and 4.5 years for offspring subjects.
RESULTS: In men with complex or frequent arrhythmias, the 6-year cumulative incidence of all-cause mortality was 38%, whereas in those free of arrhythmia it was 12%; corresponding values in women were 22% and 11%. The cumulative incidence of myocardial infarction or death due to coronary heart disease was 20% for men with and 10% for men without arrhythmia, but in women little difference was noted (5% vs. 4%). After adjustment for age and gender in a Cox proportional hazards model, subjects with complex or frequent arrhythmia were at increased risk for all-cause mortality (hazard ratio 1.80, 95% confidence interval [CI] 1.13 to 2.87, p = 0.013). After adjusting for eight clinical covariates, the increased risk for all-cause mortality remained marginally significant (hazard ratio 1.62, 95% CI 0.98 to 2.68, p = 0.058). No significant increased risk was noted for myocardial infarction or death due to coronary heart disease.
CONCLUSIONS: In subjects with left ventricular hypertrophy, the presence of asymptomatic ventricular arrhythmias was associated with higher mortality, which was statistically significant after adjusting for age and gender and marginally significant after taking into account other covariates.

Entities:  

Mesh:

Year:  1993        PMID: 8409049     DOI: 10.1016/0735-1097(93)90424-y

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

1.  Evaluation of postoperative cardiac function and long-term results in patients after aortic valve replacement for aortic valve disease with increased left ventricular mass.

Authors:  M Natsuaki; T Itoh; Y Okazaki; H Ishida; M Hamada; K Rikitake; K Naitoh
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-01

Review 2.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

3.  Development and Validation of Risk Prediction Models for Cardiovascular Events in Black Adults: The Jackson Heart Study Cohort.

Authors:  Ervin R Fox; Tandaw E Samdarshi; Solomon K Musani; Michael J Pencina; Jung Hye Sung; Alain G Bertoni; Vanessa Xanthakis; Pelbreton C Balfour; Satya S Shreenivas; Carolyn Covington; Philip R Liebson; Daniel F Sarpong; Kenneth R Butler; Thomas H Mosley; Wayne D Rosamond; Aaron R Folsom; David M Herrington; Ramachandran S Vasan; Herman A Taylor
Journal:  JAMA Cardiol       Date:  2016-04-01       Impact factor: 14.676

Review 4.  Regression of left ventricular hypertrophy: are there preferred drugs?

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

5.  Hypertension control is needed in elderly marathon runners!

Authors:  Arnoud van der Laarse; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-09-02       Impact factor: 2.357

Review 6.  Management of premature ventricular complexes.

Authors:  Albert K Chan; Mary L Dohrmann
Journal:  Mo Med       Date:  2010 Jan-Feb

Review 7.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

8.  Electrophysiological and proarrhythmic parameters in transmural canine left-ventricular needle biopsies.

Authors:  S Cora Verduyn; Jérôme G M Jungschleger; Milan Stengl; Roel L H M G Spätjens; Jet D M Beekman; Marc A Vos
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

9.  Long-term improvement of QT dispersion is unaffected by short-term changes in blood pressure during treatment of systemic hypertension with enalapril.

Authors:  Francisco Javier García Seara; José Ramón González Juanatey; José Luis Martínez Sande; Pedro Rigueiro Veloso; Antonio Pose Reino; Alfonso Varela Román; José Cabezas Cerrato; Miguel Gil de la Peña
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

10.  The prognostic significance of frequency and morphology of premature ventricular complexes during ambulatory holter monitoring.

Authors:  Georges Ephrem; Michael Levine; Patricia Friedmann; Paul Schweitzer
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-11-22       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.